Loss of cell cycle control by deregulation of cyclin-dependent kinase 2 kinase activity in Evi-1 transformed fibroblasts

Cell Growth and Differentiation

Volumn 10, Issue 9, 1999, Pages 601-610

  Kilbey, Anna ^a,b   Stephens, Victoria ^a   Bartholomew, Chris ^a,b  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE;

ANIMAL CELL; ARTICLE; CELL CYCLE; CELL DIFFERENTIATION; CELL GROWTH; CELL TRANSFORMATION; FIBROBLAST; GROWTH REGULATION; HUMAN; LEUKEMIA; LEUKEMOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTO ONCOGENE;

ANIMALS; CDC2-CDC28 KINASES; CDC25 PHOSPHATASE; CELL CYCLE PROTEINS; CELL DIVISION; CELL LINE, TRANSFORMED; CYCLIN A; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; DNA; DNA-BINDING PROTEINS; FIBROBLASTS; G1 PHASE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENES; RATS; REPRESSOR PROTEINS; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

ANIMALIA; MURINAE;

EID: 0032849789     PISSN: 10449523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Morishita, K., Parker, D. S., Mucenski, M. L., Jenkins, N. A., Copeland, N. G., and Ihle, J. N. Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukaemia cell lines. Cell, 54: 831-840, 1988.
2. Morishita, K., Parganas, E., Williams, C. L., Whittaker, M. H., Drabkin, H., Oval, J., Taetle, R., Valentine, M. B., and Ihle, J. N. Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26. Proc. Natl. Acad. Sci. USA, 89: 3937-3941, 1992.
3. Ogawa, S., Kurokawa, M., Tanaka, T., Tanaka, K., Hangaishi, A., Mitani, K., Kamada, N., Yazaki, Y., and Hirai, H. Increased Evi-1 expression is frequently observed in blastic crisis of chronic myelocytic leukemia. Leukemia (Baltimore), 10: 788-794, 1996.
4. Russell, M., List, A., Greenberg, P., Woodward, S., Glinsmann, B., Parganas, E., Ihle, J., and Taetle, R. Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations. Blood, 84: 1243-1248, 1994.
5. Matsugi, T., Morishita, K., and Ihle, J. N. Identification, nuclear localisation and DNA-binding activity of zinc finger protein encoded by the evi-1 myeloid transforming gene. Mol. Cell. Biol., 10: 1259-1264, 1990.
6. Delwel, R., Funabiki, T., Kreider, B., Morishita, K., and Ihle, J. N. Four of the seven zinc fingers of the Evi-1 myeloid transforming gene are required for sequence-specific binding to GA(C/T)AAGA(T/C)AAGATAA. Mol. Cell. Biol., 13: 4291-4300, 1993.
7. Funabiki, T., Kreider, B. L., and Ihle, J. N. The carboxyl domain of zinc fingers of the Evi-1 myeloid transforming gene binds a consensus sequence of GAAGATGAG. Oncogene, 9: 1575-1581, 1994.
8. Bartholomew, C., Kilbey, A., Clark, A. M., and Walker, M. The Evi-1 proto-oncogene encodes a transcriptional repressor activity associated with transformation. Oncogene, 14: 569-577, 1997.
9. Kilbey, A., and Bartholomew, C. Evi-1 ZF1 DNA binding activity and a second distinct transcriptional repressor region are both required for optimal transformation of Rat1 fibroblasts. Oncogene, 16: 2287-2291, 1998.
10. Kreider, B. L., Orkin, S. H., and Ihle, J. N. Loss of erythropoietin responsiveness in erythroid progenitors due to expression of the Evi-1 myeloid-transforming gene. Proc. Natl. Acad. Sci. USA, 90: 6454-6458, 1993.
11. Tanaka, T., Mitani, K., Kurokawa, M., Ogawa, S., Tanaka, K., Nishida, J., Yazaki, Y., Shibata, Y., and Hirai, H. Dual functions of the AML1/EVI1 chimeric protein in the mechanism of leukaemogenesis in t(3;21) leukaemia. Mol. Cell. Biol., 15: 2383-2392, 1995.
12. Kurokawa, M., Ogawa, S., Tanaka, T., Mitani, K., Yazaki, Y., Witte, O. N., and Hirai, H. The AML1/Evi-1 fusion protein in the t(3;21) translocation exhibits transforming activity on Rat1 fibroblasts with dependence on the Evi-1 sequence. Oncogene, 11: 833-840, 1995.
13. Mitani, K., Ogawa, S., Tanaka, T., Kurokawa, M., Yazaki, Y., and Hirai, H. Growth inhibition of leukaemic cells carrying the t(3;21) by the AML1/ EVI-1-specific antisense oligonucleotide. Br. J. Haematol., 90: 711-714, 1995.
14. Hoyt, P. R., Bartholomew, C., Davis, A. J., Yutzey, K., Gomer, L. M., Potter, S. S., Ihle, J. N., and Mucenski, M. L. The Evi1 proto-oncogene is required at midgestation for neural, heart and paraxial mesenchyme development. Mech. Dev., 65: 55-70, 1997.
15. Morishita, K., Parganas, E., Matsugi, T., and Ihle, J. N. Expression of the Evi-1 zinc finger gene in 32Dcl3 myeloid cells blocks granulocyte differentiation in response to granulocyte colony-stimulating factor. Mol. Cell. Biol., 12: 183-189, 1992.
16. Peters, G. The D-type cyclins and their role in tumourigenesis. J. Cell Sci., 18: 89-96, 1994.
17. Brechot, C. Oncogenic activation of cyclin A. Curr. Opin. Genet. Dev., 3: 11-18, 1993.
18. Levine, A. J. The tumor suppressor genes. Annu. Rev. Biochem., 62: 623-651, 1993.
19. Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., III., Johnson, B. E., and Skolnick, M. H. A cell cycle regulator involved in genesis of many tumor types. Science (Washington DC), 264: 436-440, 1994.
20. Merlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabnelson, E., Burger, P. C., Baylin, S. B., and Sidransky, D. 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/ CDKN2/MTS1 in human cancers. Nat. Med., 1: 686-692, 1995.
21. Kip1 by the viral E1A oncoprotein in TGFβ-treated cells. Nature (Lond.), 380: 262-265, 1996.
22. Funk, J. O., Waga, S., Harry, J. B., Espling, E., Stillman, B., and Galloway, D. A. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev., 11: 2090-2100, 1997.
23. Hunter, T., and Pines, J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell, 79: 573-582, 1993.
24. Morgan, D. O. Principles of CDK regulation. Nature (Lond.), 374: 131-134, 1995.
25. Harper, J. W., and Elledge, S. J. Cdk2 inhibitors in development and cancer. Curr. Opin. Genet. Dev., 6: 56-64, 1996.
26. 1 events and regulation of cell proliferation. Science (Washington DC), 246: 603-608, 1988.
27. 1 cyclins. Cell, 73: 1059-1065, 1993.
28. Bartek, J., Bartkova, J., and Lukas, J. The retinoblastoma protein pathway and the restriction point. Curr. Opin. Cell Biol., 8: 805-814, 1996.
29. LaThangue, N. B. DRTF1/E2F: an expanding family of heterodimeric transcription factors implicated in cell-cycle control. Trends Biochem. Sci., 19: 108-114, 1994.
30. Gu, Y., Rosenblatt, J., and Morgan, D. O. Cell cycle regulation of Cdk2 activity by phosphorylation of Thr160 and Tyr15. EMBO J., 11: 3995-4005, 1992.
31. 1 arrest at two points: effect on retinoblastoma protein phosphorylation and cyclin-dependent kinase 2 in normal and transformed cells. Cancer Res., 54: 5959-5963, 1994.
32. Guadagno, T. M., Ohtsubo, M., Roberts, J. M., and Assoian, R. K. A link between cyclin A expression and adhesion-dependent cell cycle progression. Science (Washington DC), 262: 1572-1575, 1993.
33. Coats, S., Flanagan, W. M., Nourse, J., and Roberts, J. M. Requirement of p27 KIP1 for restriction point control of the fibroblast cell cycle. Science (Washington DC), 272: 877-880, 1996.
34. Fang, F., Orend, G., Watanabe, N., Hunter, T., and Ruoslahti, E. Dependence of cyclin E-Cdk2 kinase activity on cell anchorage. Science (Washington DC), 271: 499-502, 1996.
35. Resnitsky, D. Ectopic expression of cyclin D1 but not cyclin E induces anchorage-independent cell cycle progression. Mol. Cell. Biol., 17: 5640-5647, 1997.
36. 1 in mammalian fibroblasts. Science (Washington DC), 259: 1908-1912, 1993.
37. 1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol. Cell. Biol., 14: 1669-1679, 1994.
38. 1-to-S transition. Mol. Cell. Biol., 15: 3463-3469, 1995.
39. Kip1. Mol. Cell. Biol., 15: 4347-4352, 1995.
40. 1-to-S phase transition. Mol. Cell. Biol., 15: 2612-2624, 1995.
41. Clark, W., and Gillespie, D. A. Transformation by v-Jun prevents cell cycle exit and promotes apoptosis in the absence of serum growth factors. Cell Growth Differ., 8: 371-380, 1997.
42. Shan, B., Chang, C., Jones, D., and Lee, W-H. The transcription factor E2F-1 mediates autoregulation of RB expression. Mol. Cell. Biol., 14: 299-309, 1994.
43. Park, K., Choe, J., Osifchin, N. E., Templeton, D. J., Robbins, P. D., and Kim, S. J. The human retinoblastoma susceptibility gene promoter is positively autoregulated by its own product. J. Biol. Chem., 269: 6083-6088, 1994.
44. KIP1 blocks cyclin E-dependent transactivation of cyclin A gene expression. Mol. Cell. Biol., 17: 407-415, 1997.
45. Lukas, J., Herzinger, T., Hansen, K., Moroni, M. C., Resnitsky, D., Helin, K., Reed, S. I., and Bartek, J. Cyclin E-induced S phase without activation of the pRb/E2F pathway. Genes Dev., 11: 1479-1492, 1997.
46. Zhao, J., Dynlacht, B., Imai, T., Hori, T., and Harlow, E. Expression of NPAT, a novel substrate of cyclin E-CDK2, promotes S-phase entry. Genes Dev., 12: 456-461, 1998.
47. Hara, E., Hall, M., and Peters, G. Cdk2-dependent phosphorylation of Id2 modulates activity of E2A-related transcription factors. EMBO J., 16: 332-342, 1997.
48. Deed, R. W., Hara, E., Atherton, G. T., Peters, G., and Norton, J. D. Regulation of Id3 cell cycle function by Cdk-2-dependent phosphorylation. Mol. Cell. Biol., 17: 6815-6821, 1997.
49. Li, Y., Graham, C., Lacy, S., Duncan, A. M., and Whyte, P. The adenovirus E1A-associated 130-kD protein is encoded by a member of the retinoblastoma gene family and physically interacts with the cyclins A and E. Genes Dev., 7: 2366-2377, 1993.
50. CIP1-related domain to bind cyclin/cdk2 and regulate interactions with E2F. Genes Dev., 9: 1740-1752, 1995.
51. Kip1. Genes Dev., 11: 1464-1478, 1997.
52. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78: 59-66, 1994.
53. Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle control. Genes Dev., 8: 9-22, 1994.
54. Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-cdk2 complex. Nature (Lond.), 382: 325-331, 1996.
55. Aprelikova, O., Xiong, Y., and Liu, E. T. Both p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by cdk-activating kinase. J. Biol. Chem., 270: 18195-18197, 1995.
56. Kip1. Gene (Amst.), 180: 113-120, 1996.
57. Johnson, D., Frame, M. C., and Wyke, J. A. Expression of the v-Src oncoprotein in fibroblasts disrupts normal regulation of the CDK inhibitor p27 and inhibits quiescence. Oncogene, 16: 2017-2028, 1998.
58. Kip1 is haplo-insufficient for tumour suppression. Nature (Lond.), 396: 177-180, 1998.
59. Kurokawa, M., Mitani, K., Irie, K., Matsuyama, T., Takahashi, T., Chiba, S., Yazaki, Y., Matsumoto, K., and Hirai, H. The oncoprotein Evi-1 represses TGF-β signalling by inhibiting Smad3. Nature (Lond.), 394: 92-96, 1998.
60. 1 cyclins D2 and D3 but not D1. Proc. Natl. Acad. Sci. USA, 90: 11513-11517, 1993.
61. cip-1 in the maintenance of stem/progenitor cells in vivo. Blood, 88: 3710-3719, 1996.
62. Firpo, E. J., Koff, A., Solomon, M. J., and Roberts, J. M. Inactivation of a Cdk2 inhibitor during interleukin 2-induced proliferation of human T lymphocytes. Mol. Cell. Biol., 14: 4889-4901, 1994.
63. 3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev., 10: 142-153, 1996.
64. Bartholomew, C., and Ihle, J. N. Retroviral insertions 90 kilobases proximal to the Evi-1 myeloid transforming gene activate transcription from the normal promoter. Mol. Cell. Biol., 11: 1820-1828, 1991.